GlassScriptPhysician profile
Luis Figueroa
NPI 1083685945
$1,556.09
in general payments reported to CMS, 2019-2025
16 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $270 · 2021: $171 · 2022: $289 · 2023: $102 · 2024: $108 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.66 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $298.30 | 2019-2020 | |
| Allergan, INC. | $153.90 | 2020-2022 | |
| Boston Scientific Corporation | $124.40 | 2019-2025 | Intracept |
| Lilly USA, LLC | $118.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $94.26 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $64.52 | 2019-2024 | Ajovy |
| Upsher-Smith Laboratories LLC | $49.40 | 2020 | |
| Pfizer INC. | $30.24 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $28.81 | 2022 | |
| Novo Nordisk INC | $27.40 | 2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $24.60 | 2022 | |
| Eisai INC. | $20.92 | 2024 | |
| Scilex Pharmaceuticals INC. | $15.87 | 2019 | |
| Lundbeck LLC | $14.09 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $9.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.